Review Article

Mitochondrial-Targeted Molecular Imaging in Cardiac Disease

Jinhui Li,1,2,3,4,5 Jing Lu,6,7 and You Zhou1

1Department of Chinese Medicine & Rehabilitation, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
2Department of Nuclear Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
3Zhejiang University Medical PET Center, Zhejiang University, Hangzhou 310009, China
4Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou 310009, China
5Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou 310009, China
6Department of Neurobiology, Key Laboratory of Medical Neurobiology of Ministry of Health of China, Hangzhou, China
7Zhejiang Province Key Laboratory of Mental Disorder's Management, Department of Psychiatry, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Correspondence should be addressed to You Zhou; zhouyou1818@foxmail.com

Received 1 January 2017; Accepted 6 February 2017; Published 30 May 2017

Academic Editor: David J. Yang

Copyright © 2017 Jinhui Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The present study aimed to discuss the role of mitochondrion in cardiac function and disease. The mitochondrion plays a fundamental role in cellular processes ranging from metabolism to apoptosis. The mitochondrial-targeted molecular imaging could potentially illustrate changes in global and regional cardiac dysfunction. The collective changes that occur in mitochondrial-targeted molecular imaging probes have been widely explored and developed. As probes currently used in the preclinical setting still have a lot of shortcomings, the development of myocardial metabolic activity, viability, perfusion, and blood flow molecular imaging probes holds great potential for accurately evaluating the myocardial viability and functional reserve. The advantages of molecular imaging provide a perspective on investigating the mitochondrial function of the myocardium invivo noninvasively and quantitatively. The molecular imaging tracers of single-photon emission computed tomography and positron emission tomography could give more detailed information on myocardial metabolism and restoration. In this study, series mitochondrial-targeted 99mTc-, 123I-, and 18F-labeled tracers displayed broad applications because they could provide a direct link between mitochondrial dysfunction and cardiac disease.

1. Introduction

Therapies for coronary artery disease (CAD) and its related disorders have benefited from the developments in modern technology over the past few decades. Noninvasive examination of myocardial molecular imaging has proved to be of great diagnostic significance and has been widely accepted [1]. Recently, functional molecular imaging, such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET), promises to expand the ability to evaluate cardiac diseases compared with the magnetic resonance imaging, ultrasound, and coronary angiography imaging modalities [2]. For instance, the assessment of myocardial function and perfusion imaging of heart ischemia using single SPECT is a widely used technique [3]. Myocardial molecular imaging using PET scanning is useful due to its predictive values; it assesses metabolic activity or viability through 18F-deoxyglucose (18F-FDG) in the living body [4]. Moreover, myocardial perfusion imaging (MPI) using SPECT is difficult to detect due to reduced myocardial blood flow (MBF) [5], which might be because of its low sensitivity. In contrast, PET imaging provides robust and sensitive measurements of MPI; it offers an excellent resolution, high sensitivity, lower tissue attenuation, and semiquantification or absolute quantification of MBF [6]. Many findings suggest using PET tracers because of their sensitivity and dynamic-imaging capabilities [7, 8] for myocardial function and viability detection [9, 10]. PET imaging is very complicated for nuclear cardiologists in contrast to SPECT perfusion imaging, which is still the most
commonly used nuclear imaging technique in clinical practice. However, precise changes in myocardial metabolism, viability, and apoptosis that reflect mitochondrial activity at the molecular imaging level have not yet been systematically summarized.

The mitochondrion comprises an outer membrane, an intermembrane space, an inner membrane, cristae, and matrix [11]. Physiologically, mitochondrial-rich heart tissue demands high energy in the form of adenosine triphosphate (ATP) and fatty acid all the time [12]. The inner membrane of mitochondria maintains a transmembrane gradient of ions and contains five complexes of essential membrane proteins, including nicotinamide adenine dinucleotide (NADH) dehydrogenase [also called mitochondrial complex I (MC-I)] [13]. The main function of MC-I is to transport NADH-reduced nicotinamide adenine along the respiratory electron transport chain, carried by proton transfer [14]. In this way, MC-I, MC-III, and MC-IV form a proton electrochemical gradient across the membrane, which is then used by MC-V to synthesize ATP [15]. Thus, inhibiting the activity of MC-I affects and reduces the synthesis of ATP (Figure 1). Moreover, MC-I inhibits the respiratory chain electron leakage resulting from the generation of reactive oxygen species, which induces oxidative damage to membrane lipids, proteins, and DNA [16]. Moreover, alterations in mitochondrial fatty acid oxidation (FAO) contribute to cardiac pathology. Therefore, mitochondrial dysfunction may reflect the dynamics of myocardial energy metabolism and apoptosis in some cardiac diseases such as myocardial infarction, chronic heart failure, and cardiomyopathy. No more existing molecular imaging data are available to describe MC-II, MC-III, MC-IV, and MC-V for cardiac diseases [17]. The outer mitochondrial membrane is thought to be the last barrier between the mitochondrion and the cytoplasm [18]. The permeability of outer membrane might regulate coupled cellular respiration and apoptosis [19].

This study intended to highlight the development of several mitochondrial-targeted SPECT and PET molecular imaging probes and to elucidate the advantages and disadvantages of molecular imaging for cardiac diseases. These probes would be presented to monitor and evaluate the changes in cardiac metabolic activity, viability, perfusion, and blood flow in preclinical and clinical practices (Table 1).

2. Mitochondrial-Targeted SPECT Agents

2.1. Mitochondrial Membrane as 99mTc-Labeled SPECT Agents. Many 99mTc-labeled mitochondrial-targeted imaging tracers have shown larger myocardial accumulations compared with other non-mitochondrial-targeted radiotracers. For instance, Galaris et al. reported that possibly cytochrome oxidase, localized in the mitochondrial inner membrane, is responsible for the binding of 99mTc-gluconate [20]. 99mTc-gluconate is mainly used for renal and myocardial scintigraphy. However, the 99mTc-gluconate is not very stable after formulation the solution compared to 99mTc-sestamibi and 99mTc-tetrofosmin. Meanwhile, 99mTc-gluconate imaging might get blur renal scintigraphy in patients with renal failure
Table 1: Mitochondria-targeted molecular imaging agents for myocardium in cardiac function.

| Radiotracers   | Modality | Location/target | Assessment | In preclinic | In clinic | QL & QT |
|----------------|----------|-----------------|------------|--------------|-----------|---------|
| $^{99m}$Tc-tetrofosmin | SPECT    | Inner membrane  | MBF        | Yes          | QL        |
| $^{99m}$Tc-MIBI     | SPECT    | Inner membrane  | MBF        | Yes          | QL        |
| $^{99m}$Tc-TMEOP    | SPECT    | Inner membrane  | MBF        | Yes          | QL        |
| $^{99m}$Tc-N-MPO    | SPECT    | Inner membrane  | MBF        | Yes          | QL        |
| $^{99m}$Tc-N-DBODC5 | SPECT    | Inner membrane  | MBF        | Yes          | QL        |
| $^{123}$I-BMIPP    | SPECT    | Fatty acid oxidation | Metabolic      | Yes          | QL        |
| $^{123}$I-CMICE-013 | SPECT    | Complex I       | MC-I receptor | Yes          | QT        |
| $^{18}$F-BCPP-EF   | PET      | Complex I       | MC-I receptor | Yes          | QT        |
| $^{18}$F-FDH5      | PET      | Complex I       | MBF        | Yes          | QT        |
| $^{18}$F-FP2OP     | PET      | Complex I       | MC-I receptor | Yes          | QT        |
| $^{18}$F-FP1OP     | PET      | Complex I       | MC-I receptor | Yes          | QT        |
| $^{18}$F-FP3OP     | PET      | Complex I       | MC-I receptor | Yes          | QT        |
| $^{18}$F-Flurpiridaz | PET    | Complex I       | MC-I receptor | Yes          | QT        |
| $^{18}$F-RP1003    | PET      | Complex I       | MC-I receptor | Yes          | QT        |
| $^{18}$F-RP1004    | PET      | Complex I       | MC-I receptor | Yes          | QT        |
| $^{18}$F-RP1005    | PET      | Complex I       | MC-I receptor | Yes          | QT        |
| $^{18}$F-FBtNP     | PET      | Inner membrane  | MBF/perfusion | Yes          | QL        |
| $^{18}$F-FETM      | PET      | Inner membrane  | MBF/perfusion | Yes          | QL        |
| $^{18}$F-FERhB     | PET      | Inner membrane  | MBF/perfusion | Yes          | QL        |
| $^{18}$F-FMBTP     | PET      | Inner membrane  | MBF/perfusion | Yes          | QL        |
| $^{18}$F-mFMBTP    | PET      | Inner membrane  | MBF/perfusion | Yes          | QL        |
| $^{18}$F-TPP       | PET      | Inner membrane  | MBF/perfusion | Yes          | QL        |
| $^{18}$F-FPTP      | PET      | Inner membrane  | MBF/perfusion | Yes          | QL        |
| $^{18}$F-FTNP      | PET      | Outer membrane  | MBF/perfusion | Yes          | QL        |
| $^{18}$F-FTHA      | PET      | Fatty acid oxidation | Metabolic      | Yes          | QL        |
| $^{18}$F-FTP       | PET      | Fatty acid oxidation | Metabolic      | Yes          | QL        |
| $^{18}$F-FTO       | PET      | Fatty acid oxidation | Metabolic      | Yes          | QL        |

MBF, myocardial blood flow; PET, positron emission tomography; SPECT, single photon emission tomography; QL, qualifiable; QT, quantifiable.

and dehydration [21]. Another classic radiotracer, $^{99m}$Tc-sestamibi ($^{99m}$Tc-MIBI), is an isocyanate compound, with a low molecular weight suitable for SPECT imaging. $^{99m}$Tc-MIBI is a lipophilic cation imaging tracer, localized primarily in mitochondria [22]. It is a passive transport process, and the myocardial uptake of $^{99m}$Tc-MIBI is approximately 1.2%–1.5% of the injected dose, showing very low redistributive properties of the tracer compared with $^{201}$TI. Most of the accumulated $^{99m}$Tc-MIBI is related to mitochondrial uptake. In contrast, part of the accumulated $^{99m}$Tc-tetrofosmin inside the rat myocardial cells enters the mitochondria [23]. Moreover, $^{99m}$Tc-MIBI perfusion imaging is considered useful for assessing mitochondrial function to monitor the severity of myocardial ischemia in patients with coronary artery stenosis [24, 25] or possible cardiotoxic drug evaluation.

Both $^{99m}$Tc-MIBI and $^{99m}$Tc-tetrofosmin are the most popular available radiotracers with widespread clinical applications all over the world and with virtually no biodistributive difference. Compared with $^{201}$TI, $^{99m}$Tc-MIBI and $^{99m}$Tc-tetrofosmin afford better count statistics and image quality. However, $^{99m}$Tc-MIBI and $^{99m}$Tc-tetrofosmin are limited by low first-pass myocardial extraction [26], resulting in underestimation of the MBF at high flow rates, and have relatively high liver uptake [27], thus making it difficult to assess myocardial perfusion, particularly in the inferior left ventricular wall.

The mitochondrial membrane is the only permeable membrane for molecules with appropriate molecular charge and shape, while the mitochondrial potentials provide a driving force for the mitochondrial localization of $^{99m}$Tc tracers. The lipophilicity might modulate the penetration capability across mitochondrial membranes [28]. $^{99m}$Tc-N(mpo)(PNP5)$^+\cdot\cdot\cdot(99m$Tc-N-MPO) and $^{99m}$Tc-[bis-(dimethoxy)propylphosphinoethyl)-ethoxyethylamine-(PNP5)] [bis (N-ethoxyethyl)-dithiocarbamato (DBODC)] nitride ($^{99m}$Tc-N-DBODC5) showed that liver clearance was fast, resulting in excellent heart/liver ratios, of which $^{99m}$Tc-N-MPO at 30 min postinjection was 12.75 ± 3.34, which was four times higher than that of $^{99m}$Tc-MIBI (2.90 ± 0.62) and two times higher than that of $^{99m}$Tc-DBODC5 (6.01 ± 1.45) in Sprague-Dawley rats [29, 30]. This indicated that $^{99m}$Tc-N-MPO has a lower first-pass extraction fraction compared with $^{99m}$Tc-MIBI. Moreover, planar imaging
studies demonstrated that $^{99m}$Tc-(CO)$_3$(15C5-PNP)$^+$ has a better liver clearance compared with $^{99m}$Tc-MIBI [31] and that $^{99m}$Tc-N(etma)(PNP5)$^+$ is a promising candidate for preclinical evaluations in rats [32]. These $^{99m}$Tc-based tracers, except for $^{99m}$Tc-DBODC5, allow SPECT images of the left ventricle and demonstrate favorable biodistribution in humans because of their high heart uptake and fast liver or lung washout features.

Recently, another subcellular distribution study showed that more than 73% of tri-methoxy-tris-pyrazolylisoniazid washout features. The left ventricle and demonstrate favorable biodistribution in diseases. In spite of information of the severity of flow impairment for cardiovascular could improve diagnosis and show a better quantitative estimation of the time to transport to the hospital, getting scanning done, and so on.

3. Mitochondrial-Targeted PET Agents

PET is the primary molecular imaging technique, with its high resolution and better sensitivity in vivo [42, 43]. Compared with other radiotracers, the $^{18}$F radiotracer could improve stability and bioavailability of tissue metabolism, enhance the bonding force, and reduce the plasma protein binding rate [44]. Incorporating $^{18}$F into a compound alters the lipophilic parameter and might increase the intrinsic activity, metabolic stability, and bioavailability [45]. Mitochondrial-targeted myocardial agents from the intake mechanism can be roughly divided into three categories: MC-I inhibitor derivatives [46], lipophilic cations [47–49], and FAO. In detail, the MC-I inhibitor analogue could bind specifically to the myocardial mitochondria; the lipophilic cation is used to enter the mitochondrial membrane potential; and FAO is a major pathway of energy production in the normal perfusion myocardium.

This study mainly addressed a large number of applications of myocardial molecular imaging of mitochondrial-targeted PET agents, such as analogues of MC-I inhibitors, $^{18}$F-labeled voltage sensor, and FAO tracer in preclinical or clinical trials.

3.1. MC-I Inhibitors as PET Agents

3.1.1. $^{18}$F-Radiolabeled Rotenone Analogue. Rotenone analogue is a potential deposited MBF tracer. The myocardial extraction, retention, washout, and uptake were evaluated. Marshall found that the uptake of $^{18}$F-flurpiridaz. Also called $^{18}$F-BMS-747158-02, is a fluorine 18-labeled agent that binds to MC-I and is also designed to be a novel myocardial perfusion PET imaging agent. The clinical trial results of $^{18}$F-flurpiridaz PET imaging showed better evaluation of patients with known or suspected CAD having rapid uptake and slow washout properties. $^{18}$F-Flurpiridaz not only exhibited high and sustained cardiac uptake that was proportional to blood flow but also showed a clear and sustained cardiac uptake correlates well with the activities of 3-hydroxyacyl-coenzyme A dehydrogenase and citrate synthase, reflecting the deterioration of both fatty acid metabolism and citrate cycle [41]. Although the pharmacokinetics of $^{123}$I-BMIPP could not be used to evaluate FAO, it could detect an antecedent cardiac ischemic abnormality, such as angina pectoris and myocardial infarction. The main advantage of $^{123}$I-BMIPP was that the abnormal heart does not shift from fatty acids to glucose consumption for 0–24 h. Therefore, the defect of BMIPP does not normalize, whereas the perfusion defect can change instantaneously between the occurrence of heart failure and actual scanning time, since one has to consider the time to transport to the hospital, getting scanning done, and so on.

3.2. FAO as $^{123}$I-Labeled SPECT Agents. $^{123}$I-labeled 15-(p-iodophenyl)-3-(R, S)-methyl pentadecanoic acid (BMIPP) is mainly trapped in the myocardium as triglycerides, depending on the ATP levels; 10%–20% of them are metabolized through α-oxidation after β-oxidation. Hirai et al. used dual-SPECT images of BMIPP and $^{201}$TI obtained 3 days and 24 days after the left coronary artery occlusion in the male Wistar-Kyoto rat model, respectively, to clarify the precise mechanism of the regulatory pathway of BMIPP in rats. The results demonstrated that BMIPP molecular imaging
in rats, rabbits, and nonhuman primates with lower lung interference and rapid liver clearance compared with $^{201}$TI or $^{99m}$Tc-MIBI [51, 52]. In phase 1 clinical studies, the mean effective dose of $^{18}$F-flurpiridaz injected at rest was similar to that of $^{18}$F-FDG [53]. $^{18}$F-Flurpiridaz had an excellent image quality with two forms of drug-induced stress imaging and with the advantages of safety, favorable biodistribution, and excellent myocardial imaging characteristics. In the clinical phase 2 trial, PET MPI with $^{18}$F-flurpiridaz was shown to have an excellent sensitivity, a greater magnitude of reversible defects, a higher percentage of good images, and a higher diagnostic certainty of interpretation compared with SPECT. However, the specificity was not significantly different (PET 76.5% versus SPECT 73.5%) [54, 55]. To evaluate the myocardial function in comparison with $^{13}$N-ammonia [56], investigators concluded that, at least in a pig model, $^{18}$F-flurpiridaz used over a wide flow range was useful for clinical PET/computed tomography (CT) applications in the workup of subjects with suspected or proven CAD. This radiotracer has been enrolled in a phase 3 trial. Furthermore, taking advantage of the early kinetics, quantification of MBF in humans with $^{18}$F-flurpiridaz was feasible over a wide range of cardiac flow in the presence or absence of stress myocardial ischemia [57]. Lately, the PET probe 2-tert-butyl-4-chloro-5-2H-pyridazin-3-one ($^{18}$F-BCPP-EF) showed a promising quantitative imaging of the MC-1 activity. The $^{18}$F-BCPP-EF and $^{18}$F-flurpiridaz uptake was higher in the heart compared with the brain, muscle, and bone 60 min after the injection. Moreover, both $^{18}$F-BCPP-EF and $^{18}$F-flurpiridaz significantly decreased after preadministering rotenone in the heart [58].

3.1.3. $^{18}$F-Fenazaquin, $^{18}$F-Pyridaben, and $^{18}$F-Chromone Analogues. Yu et al. designed and synthesized 4-(2-(4-(4-$^{18}$F-fluorobutyl)phenyl)ethoxy) quinazoline ($^{18}$F-FP1OP03), 2-tert-butyl-4-chloro-5-[4-(4-$^{18}$F-fluoro-butyloxy)-2H-pyridazin-3-one ($^{18}$F-FP1OP04), and 2-(4-(4-$^{18}$F-fluoro-butyl)-benzylsulfonyl)-3-methyl-chromen-4-one ($^{18}$F-FP1OP05) to explore three regular MC-1 inhibitor structural classes and examine MC-1 inhibitory activity of fenazaquin [59], pyridaben [60], and chromone [61]. The obtained results were identified for optimal probes. Cardiac imaging with $^{18}$F-RP1003, $^{18}$F-RP1004, and $^{18}$F-RP1005 agents in rats and rabbits allowed visualization of the heart with minimal lung interference and rapid liver activity clearance. Moreover, $^{18}$F-RP1004 PET tracer imaging showed distinct detection of the perfusion-deficit area associated with left coronary artery ligation in rats and marked liver activity washout in nonhuman primates [62]. This result was consistent with previously reported findings using radiotracer rotenone analogues. It is advisable that preliminary data should be provided first in healthy subjects for myocardial PET imaging rotenone analogue tracers.

3.1.4. Other $^{18}$F-Pyridaben Analogues. Recently, researchers used rapid screening tools to evaluate $^{18}$F-labeled pyridaben analogue tracers and yielded valuable findings. For example, $^{18}$F-labeled pyridaben analogues were labeled on alkyl side chain rather than directly on the pyridazinone moiety [63]. Mou et al. evaluated the biodistribution and metabolic stability of 2-tert-butyl-5-[2-(2-$^{18}$F-fluoroethoxy) ethoxy-benzyl]-4-chloro-2H-pyridazin-3-one ($^{18}$F-FP2OP) in mice and verified the results with autoradiography ex vivo. The data from high-yield and radiochemical purity studies (>98%) and biodistribution studies showed that $^{18}$F-FP2OP PET has a significantly high heart uptake; the imaging showed a clear outline of the myocardium in a healthy Chinese miniswine [64]. This demonstrated the potential value of $^{18}$F-FP2OP as a myocardial imaging tracer. Another study prompted that 2-tertbutyl-4-chloro-5-(4-(2-(2-$^{18}$F-fluoro-ethoxy)) benzyl)-2H-pyridazin-3-one ($^{18}$F-FP3OP) had a better metabolic stability and faster clearance in myocardium compared with $^{18}$F-FP2OP. However, 2-tert-butyl-4-chloro-5-(4-(2-$^{18}$F-fluoro-ethoxy)) benzyl)-2H-pyridazin-3-one ($^{18}$F-FP1OP) is worth developing as a new PET MPI tracer owing to its superiority over $^{18}$F-FP3OP [65]. The instability of $^{18}$F-FP2OP in water limits its range of applications. These two lipophilic and neutral agents of $^{18}$F-FP1OP and $^{18}$F-FP3OP were successfully prepared with high radiochemical yield (>50%) and high purity (>98%). Fenazaquin might have a similar high affinity for the target of rotenone [46]. A cluedub quinazoline and $^{18}$F-labeled 4-fluorobutyl analogue, designed by Purohit et al., showed a high and rapid heart uptake, fast liver clearance, and low blood uptake in the rat.

Thus, an outstanding MC-1 tracer may have several properties: (a) quick myocardial uptake after injection; (b) longer retention in the myocardium; (c) good-quality imaging; (d) uniform radioactive distribution in the ventricular wall; (e) fast radioactivity clearance outside of the heart, such as blood pool, lung, and liver; and (f) no requirement of onsite accelerator production. However, how $^{18}$F-flurpiridaz meets all the aforementioned requirements in the clinical setting compared with other new MC-1 inhibitor tracers who have a hard time getting into the clinic remains to be evaluated. This may be attributed to its better biological characteristics or high sensitivity, but potentially lagging specificity for the detection of CAD [66].

3.2. $^{18}$F-Labeled Voltage Sensor as PET Agents. Mitochondria play a fundamental role in energy metabolism, apoptosis, and oxidative stress [67] in the myocardium, and the mitochondrial inner membrane maintains a transmembrane gradient of ions and integrity of the mitochondrion itself. Measuring the mitochondrial potential shows the development in MBF and perfusion detection and evaluation [68]. Lipophilic cations utilize the mitochondrial transmembrane potential across the cell membrane by passive diffusion and then rapidly accumulate in the myocardium. Hence, $^{18}$F-labeled lipophilic cation radiotracers are useful for facilitating a clearer appreciation of the myocardial function analysis of a wide range of metabolic dysfunction to the earlier apoptosis-related mitochondrial dysfunction. In these $^{18}$F-labeled voltage sensor tracers, the active triphenyl phosphonium (TP) group is widely studied. The TP molecule shows...
electropositive potential and could easily penetrate into the mitochondrial inner membrane, which is a very electronegative organelle [69]. Therefore, TP molecules were commonly used as a labeling radiotracer for apoptosis imaging through detecting mitochondrial membrane potential loss.

3.2.1. 18F-Fluorobenzyl Triphenyl Phosphonium. In the mitochondrial or intrinsic signaling pathway for apoptosis, the inner mitochondrial transmembrane potential (ΔΨm) [70] is usually lost, and the mitochondrial release of cytochrome c eventually triggers the activation of caspase. In fact, the release of the apoptosis-inducing factor is dependent on the disruption of ΔΨm early in the apoptotic pathway [71]. Madar et al. first characterized the ability of the novel PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium (18F-FBnTP) and found a novel radionuclide for PET cardiac imaging in the dog [72, 73], with rapid kinetics, uniform myocardial distribution, and favorable organ biodistribution in vitro and in vivo [74]. Further research yielded that the ischemic region by 18F-FBnTP remained stable for at least 45 min and matched the histologically defined ischemic area. This lack of significant redistribution suggests a sufficient time window for future clinical protocols with a tracer injection remote from the scanner, such as in a stress testing laboratory after transient coronary occlusion [75]. Therefore, in a clinical trial practice, 18F-FBnTP PET imaging might be one of the most used techniques for myocarditis apoptosis.

3.2.2. 18F-Fluoropentyl-Triphenyl Phosphonium. The TP cations play a crucial role in detecting the mitochondrial voltage sensor in the outer membrane of myocardial imaging. 18F-Fluoropentyl-triphenyl phosphonium (18F-FPTP) allows a high throughput and a wide distribution of PET myocardial imaging [76]. 4-[18F]-Fluorophenyl-triphenyl phosphonium ion also showed rapid blood clearance and high levels of accumulation in the heart at 30 min. The radioactivity uptake in the heart was 1.64%, 1.51%, and 1.57% ID/g at 5, 30, and 60 min in rats, respectively [77]. More original TP cation tracers should be synthesized and evaluated for healthy subjects and patients with cardiac diseases.

3.2.3. 4-18F-Tetraphenyl Phosphonium. TP is useful for measuring ΔΨm in vitro. Although no gold standard method exists for measuring myocardial ΔΨm, measuring ΔΨm has a potential role in assessing heart pathophysiology and therapy as well as myocardial viability. Gurin et al. reported that 4-18F-tetraphenyl phosphonium (18F-TPP), as a blood flow tracer, was useful in vivo in the PET imaging measurement of ΔΨm for assessing the relative [78], but not absolute MBF.

3.2.4. 18F-Labeled (2-(2-Fluoroethoxy)ethyl)tris(4-methoxyphenyl) Phosphonium. Another 18F-labeled phosphonium cation agent has been developed due to the technical limitations of SPECT imaging. An 18F-labeled phosphonium cation was added to the alkyl group, which increased the hydrophobicity, liposolubility, and hydrophobic interaction between the TP cation and the lipid core. Kim et al. showed that the radiochemical purity was 98% with a 10%–20% yield.

The cellular uptake assay showed the preferential uptake of 18F-labeled (2-(2-fluoroethoxy)ethyl)tris(4-methoxyphenyl) phosphonium (18F-FETMP) in cardiomyocytes, and their biodistribution showed preferential accumulation in the myocardium using small-animal PET imaging studies in mice and rats. The results suggested that 18F-FETMP would be a promising candidate for myocardial imaging [79]. Interestingly, the biodistribution properties and preferential uptake of 18F-labeled (2-(2-fluoroethoxy) ethyl) triphenyl phosphonium cations in cardiomyocytes were similar to those of 18F-FETMP cations in living rats [80]. Moreover, 18F-labeled (6-fluorohexyl) triphenyl phosphonium cations showed a low radiochemical yield (15%–20%) [81] and hence require an improvement in the extraction technology in the future. Further evaluation of novel phosphonium cations needs to be carried out in healthy subjects and patients.

3.2.5. 18F-4-(Fluoromethyl)benzyl Triphenyl Phosphonium and 18F-3-(Fluoromethyl)benzyltrisphenyl Phosphonium. TP cations always accumulate in the mitochondria of the heart in response to the negative inner transmembrane potentials. Recently, Zhang’s group reported 18F-4-(fluoromethyl)benzyl triphenyl phosphonium (18F-FMBTP) and 18F-3-(fluoromethyl)benzyltrisphenyl phosphonium (18F-mFMBTP) [82] as potential MPI PET agents, which were obtained in a high radiolabeling yield (~50%) with a good radiochemical purity (~99%) in less than 60 min. Most importantly, these new TP cations were synthesized by the one-pot-labeling procedure and showed high initial radioactivity accumulation in the heart with a rapid nontarget tissue clearance.

3.2.6. 18F-Fluorodihydrorotenone B. 18F-labeled probes for PET imaging have become important tools for directly measuring the ΔΨm [83]. Heinrich et al. developed these fluorescent dyes for MPI. They explored the biodistribution and stability of 18F-labeled rhodamine B, also called 3-fluoropropyl ester of rhodamine B, and found lipophilic cation accumulation in the mitochondria in proportion to the mitochondrial membrane potential [84]. The tracer concentration 1h after injection in the liver was initially greater than that in the heart but decreased over time, which were approximately equal. Throughout this period, the concentration of the tracer in the myocardium remained stable without washout [63]. These findings suggested that the prosthetic group [85], partly due to the diethylene glycol ester, was superior in terms of in vitro stability and pharmacokinetics than ethyl ester for labeled rhodamine B.

3.3. FAO as PET Agents. Fatty acid metabolism is a major pathway of energy production in regular perfusion myocardium. In the myocardium, the long-chain fatty acids must be attached to a hitch called coenzyme A (CoA) by enzymes called synthetases in the mitochondria. Therefore, the fatty acid has been renamed as acyl-CoA. β-Oxidation of fatty acids mainly occurs within the mitochondria. Products of β-oxidation are preferentially channeled to the tricarboxylic acid cycle, away from mitochondrial
efflux, via carnitine palmitoyltransferase, which is an enzyme that catalyzes the rate-limiting step in mitochondrial FAO [86]. Hypoxia could prevent long-chain fatty acid-induced accumulation of messenger-RNA encoding muscle carnitine palmitoyltransferase I [87]. The understanding of the rates of myocardial uptake and fatty acid metabolism has led to the development of mitochondrial-targeted fatty acid tracers.

3.3.1. 14(R, S).18F-6-Thia-heptadecanoic Acid. 18F-Fluorothia-
6-heptadecanoic acid (18F-FTHA) is a PET tracer with an uptake rate proportional to the rate of myocardial free fatty acid utilization. The results indicated that the metabolic trapping of 18F-FTHA in the myocardium occurred subsequent to its entry into the mitochondrion [88]. Noninvasive assessment of myocardial FAO with PET and the development of an appropriate long-chain fatty acid tracer might provide a research and diagnostic tool for evaluating FAO in humans.

3.3.2. 16-18F-Fluoro-4-thia-palmitate. Degrado et al. developed 16-18F-fluoro-4-thia-palmitate (18F-FTP) and showed that moving the sulfur heteroatom to the carbon at position 4 permitted retention of the metabolic trapping character of the tracer [89]. Moreover, they demonstrated that 18F-FTP provides high ratios of myocardium activity to the background activities of blood and the lung. Furthermore, the inhibition of mitochondrial β-oxidation by oxygen deprivation led to a substantial decrease in the 18F-FTP lumped constant (LC) values [90], which is introduced by analogy to the LC used for the estimation of the glucose metabolic rate with deoxyglucose analog radiotracers quantitatively. Developing a novel probe for the myocardial mitochondrial function is particularly necessary for patients with ischemic heart disease.

3.3.3. 18-18F-Fluoro-4-thia-oleate. A study on novel 4-thia
oleate analogue, 18F-18F-fluoro-4-thia-oleate (18F-FTO), eval-
uated the difference in biodistribution between fasted and fed rats and found that the livers of fed rats showed a 29% lower uptake. Clearance from the liver was seen between 30 and 120 min in fasted animals, whereas the heart uptake was maintained at a minimal level using small-animal PET/CT. Moreover, a higher heart-to-liver radioactivity concentration ratio was seen with 18F-FTO, and the blood-pool data was not corrected for the spillover effect from the myocardium [91]. These results indicated that the PET images of 18F-FTO accumulation in the rat myocardium were clearly superior to those of 18F-FTP. The 18F-FTO PET imaging would show better radio characteristics for myocardium in humans.

4. Summary and Outlook

The uptake of 99mTc tracers depends on the mitochondrial membrane integrity of the cell and is seldom influenced by metabolic effects as long as the integrity of the cell membrane is not damaged, even when myocardial cell ischemia, hypoxia, or another condition exists. In this study, 99mTc tracers could be used as reliable indicators of myocardial activity by myocardium stunning. Using 99mTc SPECT for evaluating myocardial viability might underestimate the vi-
ability of hibernating myocardium [92, 93]. In contrast, the properties of 18F, including active myocardium uptake and redistribution potential, make it a physiological myocardial tracer.

Although PET imaging has a higher spatial resolution than SPECT with high values of sensitivity [94, 95] and allows quantifying the basal and hyperemic regional MBF from metabolism to apoptosis [96], the single PET modality for a variety of clinical applications is not enough. MPI with a hybrid CT device is considerably more expensive and can obtain same-setting measurement of the coronary artery calcium score [97]. However, one obstacle to the wider use of PET/CT is the cost of producing radiopharmaceuticals used for PET imaging in developing countries, compared with SPECT/CT imaging. PET/magnetic resonance imaging (MRI) or SPECT/CT modalities have many advantages in cardiac sarcoidosis or myocardial viability imaging and should be considered for younger patients, as they involve less exposure to radiation [98]. PET/CT or PET/MRI imaging is predicted to extend application from the characterization of atherosclerotic plaques to the efficiency of stem cell therapies with the emergence of novel mitochondrial-targeted tracers [99].

The excellent mitochondrial-targeted myocardial trac-
ers with less liver uptake, higher first-pass extraction, and improved redistribution profile are welcome [28]. Moreover, tracers through a suitable alteration of the molecular properties such as lipophilicity, volume, and charge are needed. 18F-TPP was synthesized through direct nucleophilic substitution of no-carrier-added 18F-fluoride with the pre-
cursor 4-nitrophenoxy-triphenyl phosphonium [77], whereas 18F-labeled fluoroalkyl triphenyl phosphonium salts ([F-
FATPs) were synthesized through two-step simple nucle-
ophilic substitution reactions [100]. For both 18F-TPP and 18F-FATPs, the average radiochemical yield was 10%–30% and the specific activity was >6 TBq/μmol at the end of the synthesis after purification. The total synthesis time was 60 min, and the radiochemical purity was greater than 95%. However, no explicit proof was found regarding one tracer or modality being superior to the other. Physicians involved in nuclear cardiology should review the relative advantages and disadvantages of all 18F-labeled myocardial tracers before choosing one for their healthy subjects or patients. Despite 18F-FBnTP, 18F-FPTP, and 18F-FETMP having synthetic low efficiency, it is expected that a number of novel 18F-labeled tracers would emerge, with better phar-
macokinetic properties of MC-I inhibitor after structural modification.

Overall, the mitochondrial-targeted myocardial molecu-
lar imaging of the cardiac processes from myocardial metabolism and apoptosis to ventricular remodeling might be helpful in clinical practices in the future. Each of the available agents has unique advantages and disadvantages that should be considered to ensure its optimal application. The 99mTc-N-DBODCS and 18F-flurpiridaz are commonly used in the clinic for myocardial imaging.
Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This research was partly sponsored by grants from the National Science Foundation of China (NSFC) (nos. 81202947 and 30672396), Health Science and Technology Project of Zhejiang Province (no. 2013KYA096), and the Ministry of Science and Technology of China (nos. 2006DFB32940 and 2011CB504400). The authors are also grateful to Ms. W. T. P. Verweij for her secretarial assistance.

References

[1] M. H. Al-Mallah, A. Sitek, S. C. Moore, M. Di Carli, and S. Dorbala, “Assessment of myocardial perfusion and function with PET and PET/CT,” *Journal of Nuclear Cardiology*, vol. 17, no. 3, pp. 498–513, 2010.

[2] I. Y. Chen and J. C. Wu, “Cardiovascular molecular imaging: focus on clinical translation,” *Circulation*, vol. 123, no. 4, pp. 425–443, 2011.

[3] A. Fathala, “Myocardial perfusion scintigraphy: techniques, interpretation, indications and reporting,” *Annals of Saudi Medicine*, vol. 31, no. 6, pp. 625–634, 2011.

[4] A. L. Baggish and C. A. Boucher, “Radiopharmaceutical agents for myocardial perfusion imaging,” *Circulation*, vol. 118, no. 16, pp. 1668–1674, 2008.

[5] G. A. Beller and D. D. Watson, “A welcomed new myocardial perfusion imaging agent for positron emission tomography,” *Circulation*, vol. 119, no. 17, pp. 2299–2301, 2009.

[6] M. C. Ziadi and R. S. B. Beanlands, “The clinical utility of assessing myocardial blood flow using positron emission tomography,” *Journal of Nuclear Cardiology*, vol. 17, no. 4, pp. 571–581, 2010.

[7] R. S. B. Beanlands and G. Youssef, “Diagnosis and prognosis of coronary artery disease: PET is superior to SPECT: Pro.,” *Journal of Nuclear Cardiology*, vol. 17, no. 4, pp. 683–695, 2010.

[8] M. D. Cerqueira, “Diagnosis and prognosis of coronary artery disease: PET is superior to SPECT: Con,” *Journal of Nuclear Cardiology*, vol. 17, no. 4, pp. 678–685, 2010.

[9] I. Valenta, A. Quercioli, G. Vincenti et al., “Structural epicardial disease and microvascular function are determinants of an abnormal longitudinal myocardial blood flow difference in cardiovascular risk individuals as determined with PET/CT,” *Journal of Nuclear Cardiology*, vol. 17, no. 6, pp. 1023–1033, 2010.

[10] O. Gaemperli and P. A. Kaufmann, “PET and PET/CT in cardiovascular disease,” *Annals of the New York Academy of Sciences*, vol. 1228, no. 1, pp. 109–136, 2011.

[11] V. Jazbutyte, “Mitochondrial dynamics: molecular mechanisms and the role in the heart,” *Minerva Cardioangioligica*, vol. 58, no. 2, pp. 231–239, 2010.

[12] S. K. Bandyopadhyay and A. Dutta, “Mitochondrial medicine,” *Journal of Association of Physicians of India*, vol. 58, no. 4, pp. 237–241, 2010.

[13] A. Mayevsky and G. G. Rogatsky, “Mitochondrial function in vivo evaluated by NADH fluorescence: from animal models to human studies,” *American Journal of Physiology—Cell Physiology*, vol. 292, no. 2, pp. C615–C640, 2007.

[14] J. A. M. Smet tink, L. W. P. J. van den Heuvel, W. J. H. Koopman, L. G. J. Nijtmans, C. Ugalde, and P. H. G. M. Willems, “Cell biological consequences of mitochondrial NADH:ubiquinone oxidoreductase deficiency,” *Current Neurovascular Research*, vol. 1, no. 1, pp. 29–40, 2004.

[15] K. M. Davies, M. Strauss, B. Daum et al., “Macromolecular organization of ATP synthase and complex I in whole mitochondria,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 34, pp. 14123–14126, 2011.

[16] P. Smits, J. Smetink, and L. Van Den Heuvel, “Mitochondrial translation and beyond: processes implicated in combined oxidative phosphorylation deficiencies,” *Journal of Biomedicine and Biotechnology*, vol. 2010, Article ID 737385, 24 pages, 2010.

[17] M. Forkink, G. R. Manjeri, D. C. Liemburg-Apers et al., “Mitochondrial hyperpolarization during chronic complex i inhibition is sustained by low activity of complex II, III, IV and v,” *Biochimica et Biophysica Acta—Bioenergetics*, vol. 1837, no. 8, pp. 1247–1256, 2014.

[18] V. V. Lemeshko, “Channeling of mitochondrial energy in cardiac and cancer cells by the metabolically-dependent outer membrane potential,” *Biophysical Journal*, vol. 108, no. 2, p. 607a, 2015.

[19] M. G. Vander Heiden, N. S. Chandel, X. X. Li, P. T. Schumacker, M. Colombini, and C. B. Thompson, “Outer mitochondrial membrane permeability can regulate coupled respiration and cell survival,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 9, pp. 4666–4671, 2000.

[20] D. Galaris, M. Grandinson, U. Söderlund, N. E. Ahlborg, and J. Rydström, “Binding of 99mTc-glucenate to heart mitochondria,” *European Journal of Nuclear Medicine*, vol. 8, no. 1, pp. 4–9, 1983.

[21] P. Giogetti, A. Lupo, E. Santeusanio, C. L. Schiavo, M. Zamboni, and A. Marabini, “99Tc-Ca-Glucenate renal scintigraphy in patients with chronic renal failure,” *La Ricerca in Clinica e in Laboratorio*, vol. 10, no. 2, pp. 447–457, 1980.

[22] P. Crane, R. Laliberté, S. Heminway, M. Thoelen, and C. Orlandi, “Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention,” *European Journal of Nuclear Medicine*, vol. 20, no. 1, pp. 20–25, 1993.

[23] A. S. Arbab, K. Koizumi, K. Toyama, T. Araki, and T. Araki, “Technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 uptake in rat myocardial cells,” *Journal of Nuclear Medicine*, vol. 39, no. 2, pp. 266–271, 1998.

[24] R. Tanaka, T. Nakamura, S. Chiba et al., “Clinical implication of reverse redistribution on 99mTc-sestami bi images for evaluating ischemic heart disease,” *Annals of Nuclear Medicine*, vol. 20, no. 5, pp. 349–356, 2006.

[25] S. Matsuo, I. Nakae, T. Tsutamoto, N. Okamoto, and M. Horie, “A novel clinical indicator using Tc-99m sestami bi for evaluating cardiac mitochondrial function in patients with cardiomyopathies,” *Journal of Nuclear Cardiology*, vol. 14, no. 2, pp. 215–220, 2007.

[26] W. M. Schaefer, D. Moka, H. A. Brockmann, K. Schomaecker, and H. Schicha, “201Tl, 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-furifosmin: relative retention and clearance kinetics in retrogradely perfused guinea pig hearts,” *Nuclear Medicine and Biology*, vol. 29, no. 2, pp. 243–254, 2002.

[27] O. O. Sogbee, M. Pelletier-Galarneau, T. H. Schindler, L. Wei, R. G. Wells, and T. D. Ruddy, “New SPECT and PET radio-pharmaceuticals for imaging cardiovascular disease,” *BioMed Research International*, vol. 2014, Article ID 942960, 2014.
A. Brosiat, M. Ruiz, N. C. Goodman et al., “Myocardial uptake of 18F-fluorodihydrorotenone during vasodilator stress in dogs with critical coronary stenoses,” *Circulation: Cardiovascular Imaging*, vol. 4, no. 6, pp. 685–692, 2011.

T. Hirai, R. Nohara, S. Ogho et al., “Serial evaluation of fatty acid metabolism in rats with myocardial infarction by pinhole SPECT,” *Journal of Nuclear Cardiology*, vol. 8, no. 4, pp. 472–481, 2001.

W. K. Hagmann, “The many roles for fluorine in medicinal chemistry,” *Journal of Medicinal Chemistry*, vol. 51, no. 15, pp. 4359–4369, 2008.

[27] T. Higuchi, S. G. Nekolla, M. M. Huisman et al., “A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats,” *Journal of Nuclear Medicine*, vol. 49, no. 10, pp. 1715–1722, 2008.

[28] Y.-S. Kim, F. Wang, and S. Liu, “Minimizing liver uptake of cationic 99mTc radiotracers with ether and crown ether functional groups,” *World Journal of Hepatology*, vol. 2, no. 1, pp. 21–31, 2010.

[29] W.-C. Zhang, W. Fang, B. Li, X.-B. Wang, and Z.-X. He, “Experimental study of 99mTc(PNPS)(DBODC)+ as a new myocardial perfusion imaging agent,” *Cardiology*, vol. 112, no. 2, pp. 89–97, 2009.

[30] K. Hatada, L. M. Riou, M. Ruiz et al., “99mTc-N-DBODCS, a new myocardial perfusion imaging agent with rapid liver clearance: comparison with 99mTc-sestamibi and 99mTc-tetrofosmin in rats,” *Journal of Nuclear Medicine*, vol. 45, no. 12, pp. 2095–2100, 2004.

[31] Z. He, W.-Y. Hsieh, Y.-S. Kim, and S. Liu, “Evaluation of novel cationic 99mTc(1)-tricarbonyl complexes as potential radiotracers for myocardial perfusion imaging,” *Nuclear Medicine and Biology*, vol. 33, no. 8, pp. 1045–1053, 2006.

[32] Y.-S. Kim, Z. He, W.-Y. Hsieh, and S. Liu, “Impact of bidentate chelators on lipophilicity, stability, and biodistribution characteristics of cationic 99mTc-nitrido complexes,” *Bioconjugate Chemistry*, vol. 18, no. 3, pp. 929–936, 2007.

[33] F. Mendes, L. Gano, C. Fernandes, A. Paulo, and I. Santos, “Studies of the myocardial uptake and excretion mechanisms of a novel 99mTc heart perfusion agent,” *Nuclear Medicine and Biology*, vol. 39, no. 2, pp. 207–213, 2012.

[34] L. R. Goethals, I. Santos, V. Caveliers et al., “Rapid hepatic clearance of 99mTc-TMEOP: a new candidate for myocardial perfusion imaging,” *Contrast Media and Molecular Imaging*, vol. 6, no. 4, pp. 178–188, 2011.

[35] S. Fleischmann, P. Koepfli, M. Namdar, C. A. Wyss, R. Jenni, and P. A. Kaufmann, “Gated 99mTc-tetrofosmin SPECT for discriminating infarct from artifact in fixed myocardial perfusion defects,” *Journal of Nuclear Medicine*, vol. 45, no. 5, pp. 754–759, 2004.

[36] H. Ma, S. Li, Z. Wu, J. Liu, H. Liu, and X. Guo, “Comparison of 99mTc-N-DBODC5 and 99mTc-MIBI of myocardial perfusion imaging for diagnosis of coronary artery disease,” *BioMed Research International*, vol. 2013, Article ID 145427, 2013.

[37] R. G. Wells, L. Wei, J. Petryk et al., “Flow-dependent uptake of [123I]-CMICE-013, a novel SPECT perfusion agent, compared with standard tracers,” *Journal of Nuclear Medicine*, vol. 56, no. 5, pp. 764–770, 2015.

[38] H. F. VanBrocklin, S. M. Hanrahan, J. D. Enas, E. Randan, and J. P. O’Neil, “Mitochondrial avid radiophores. Preparation and evaluation of 77I-(Z)-[125I]iodorotenone and 77I-(Z)-[125I]iodorotenol,” *Nuclear Medicine and Biology*, vol. 34, no. 1, pp. 109–116, 2007.

[39] L. Wei, C. Bensimon, J. Lockwood et al., “Synthesis and characterization of 123I-CMICE-013: a potential SPECT myocardial perfusion imaging agent,” *Bioorganic and Medicinal Chemistry*, vol. 21, no. 11, pp. 2903–2911, 2013.

[40] A. Broisat, M. Ruiz, N. C. Goodman et al., “Myocardial uptake of 77I-(Z)-[122I]iodorotenone during vasodilator stress in dogs with critical coronary stenoses,” *Circulation: Cardiovascular Imaging*, vol. 4, no. 6, pp. 685–692, 2011.

[41] T. Hirai, R. Nohara, S. Ogho et al., “Serial evaluation of fatty acid metabolism in rats with myocardial infarction by pinhole SPECT,” *Journal of Nuclear Cardiology*, vol. 8, no. 4, pp. 472–481, 2001.

[42] W. K. Hagmann, “The many roles for fluorine in medicinal chemistry,” *Journal of Medicinal Chemistry*, vol. 51, no. 15, pp. 4359–4369, 2008.
T. Mou, H. Jing, W. Yang et al., “Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for PET,” *Journal of Nuclear Medicine*, vol. 53, no. 11, pp. 1779–1785, 2012.

D. Y. Kim, H.-J. Kim, K.-H. Yu, and J.-J. Min, “Synthesis of [18F]-labeled (2-(2-fluoroethoxy)ethyl)tris(4-methoxyphenyl) phosphonium cation as a potential agent for positron emission tomography myocardial imaging,” *Nuclear Medicine and Biology*, vol. 39, no. 7, pp. 1093–1098, 2012.

D. Y. Kim, H.-J. Kim, K.-H. Yu, and J.-J. Min, “Synthesis of [18F]-labeled (6-fluorohexyl)triphosphonium cation as a potential agent for myocardial imaging using positron emission tomography,” *Bioconjugate Chemistry*, vol. 23, no. 3, pp. 431–437, 2012.

Z. Zhao, Q. Yu, T. Mou et al., “Highly efficient one-pot labeling of new phosphonium cations with fluorine-18 as potential PET agents for myocardial perfusion imaging,” *Molecular Pharmaceutics*, vol. 11, no. 2, pp. 382–383, 2014.

S. W. Perry, J. P. Norman, J. Barbieri, E. B. Brown, and H. A. Gelbard, “Mitochondrial membrane potential probes and the proton gradient: a practical usage guide,” *BioTechniques*, vol. 50, no. 2, pp. 189–194, 2011.

T. K. Heinrich, V. Gottumukkala, E. Snay et al., “Synthesis of fluorine-18 labeled rhodamine B: a potential PET myocardial perfusion imaging agent,” *Applied Radiation and Isotopes*, vol. 68, no. 1, pp. 96–100, 2010.
for positron emission tomography (PET),” *Journal of Medicinal Chemistry*, vol. 55, no. 24, pp. 11004–11012, 2012.

[86] J. M. O’Donnell, N. M. Alpert, L. T. White, and E. Douglas Lewandowski, “Coupling of mitochondrial fatty acid uptake to oxidative flux in the intact heart,” *Biophysical Journal*, vol. 82, no. 1, pp. 11–18, 2002.

[87] J. M. Huss, F. H. Levy, and D. P. Kelly, “Hypoxia inhibits the peroxisome proliferator-activated receptor α/retinoid X receptor gene regulatory pathway in cardiac myocytes: a mechanism for O2-dependent modulation of mitochondrial fatty acid oxidation,” *Journal of Biological Chemistry*, vol. 276, no. 29, pp. 27605–27612, 2001.

[88] T. R. DeGrado, H. H. Coenen, and G. Stocklin, “(R,S)-[18F]Fluoro-6-thia-heptadecanoic acid (FTHA): evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids,” *Journal of Nuclear Medicine*, vol. 32, no. 10, pp. 1888–1896, 1991.

[89] T. R. DeGrado, S. Wang, J. E. Holden, R. J. Nickles, M. Taylor, and C. K. Stone, “Synthesis and preliminary evaluation of 18F-labeled 4-thia palmitate as a PET tracer of myocardial fatty acid oxidation,” *Nuclear Medicine and Biology*, vol. 27, no. 3, pp. 221–231, 2000.

[90] C. K. Ng, J. E. Holden, T. R. DeGrado, D. M. Raffel, M. L. Kornguth, and S. J. Gatley, “Sensitivity of myocardial fluoro deoxy glucose lumped constant to glucose and insulin,” *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 260, no. 2, part 2, pp. H593–H603, 1991.

[91] T. R. DeGrado, F. Bhattacharyya, M. K. Pandey, A. P. Belanger, and S. Wang, “Synthesis and preliminary evaluation of 18F-fluoro-4-thia-oleate as a PET probe of fatty acid oxidation,” *Journal of Nuclear Medicine*, vol. 51, no. 8, pp. 1310–1317, 2010.

[92] M. Bountioukos, A. F. L. Schinkel, J. J. Bax et al., “Pulsed wave tissue Doppler imaging for the quantification of contractile reserve in stunned, hibernating, and scarred myocardium,” *Heart*, vol. 90, no. 5, pp. 506–510, 2004.

[93] R. E. Thornhill, F. S. Prato, and G. Wisenberg, “The assessment of myocardial viability: a review of current diagnostic imaging approaches,” *Journal of Cardiovascular Magnetic Resonance*, vol. 4, no. 3, pp. 381–410, 2002.

[94] J. MacHac, “Cardiac positron emission tomography imaging,” *Seminars in Nuclear Medicine*, vol. 35, no. 1, pp. 17–36, 2005.

[95] M. E. Di Carli and R. Hachamovitch, “New technology for noninvasive evaluation of coronary artery disease,” *Circulation*, vol. 115, no. 4, pp. 1464–1480, 2007.

[96] J. Knutti, S. Kajander, M. Mäki, and H. Ukkonen, “Quantification of myocardial blood flow will reform the detection of CAD,” *Journal of Nuclear Cardiology*, vol. 16, no. 4, pp. 497–506, 2009.

[97] K. A. Bybee, J. Lee, R. Markiewicz et al., “Diagnostic and clinical benefit of combined coronary calcium and perfusion assessment in patients undergoing PET/CT myocardial perfusion stress imaging,” *Journal of Nuclear Cardiology*, vol. 17, no. 2, pp. 188–196, 2010.

[98] C. Rischpler and S. G. Nekolla, “PET/MRI for cardiac imaging: possibilities and limits,” *Radiologe*, vol. 53, no. 8, pp. 691–698, 2013.

[99] S. G. Nekolla, A. Martinez-Moeller, and A. Saraste, “PET and MRI in cardiac imaging: from validation studies to integrated applications,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 36, supplement 1, pp. S121–S130, 2009.

[100] D.-Y. Kim and J.-J. Min, “Synthesis and evaluation of 18F-labeled fluoroalkyl triphenylphosphonium salts as mitochondrial voltage sensors in PET myocardial imaging,” *Methods in Molecular Biology*, vol. 1265, pp. 59–72, 2015.